J
Jean-Pierre Bergerat
Publications - 15
Citations - 815
Jean-Pierre Bergerat is an academic researcher. The author has contributed to research in topics: Regimen & Transplantation. The author has an hindex of 6, co-authored 15 publications receiving 789 citations.
Papers
More filters
Journal ArticleDOI
Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients.
Raoul Herbrecht,Valérie Letscher-Bru,Corina Oprea,Bruno Lioure,J. Waller,Odile Villard,Kun-Lun Liu,Shanti Natarajan-Amé,Patrick Lutz,Patrick Dufour,Jean-Pierre Bergerat,Ermanno Candolfi +11 more
TL;DR: Galactomannan ELISA seems less sensitive than previously described, and sensitivity can be further reduced by the presence of anti-Aspergillus antibodies.
Journal ArticleDOI
Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis
Yasmine Nivoix,Michel Velten,Valérie Letscher-Bru,Alireza Moghaddam,Shanti Natarajan-Amé,Cécile Fohrer,Bruno Lioure,Karin Bilger,Philippe Lutun,Luc Marcellin,Anne Launoy,Guy Freys,Jean-Pierre Bergerat,Raoul Herbrecht +13 more
TL;DR: Kohno et al. as discussed by the authors retrospectively reviewed 385 cases of suspected or documented aspergillosis that occurred during a 9-year period and identified 289 episodes that fulfilled the criteria for possible, probable, or proven invasive Aspergillus active antifungal drug treatment.
Journal ArticleDOI
Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen
Cécile Fohrer,Sophie Caillard,Argyro Koumarianou,Bernard Ellero,Marie Lorraine Woehl-Jaegle,Carole Meyer,Eric Epailly,Marie-Pierre Chenard,Bruno Lioure,Shanti Natarajan-Amé,Frédéric Maloisel,Philippe Lutun,Romain Kessler,Bruno Moulin,Jean-Pierre Bergerat,Philippe Wolf,Raoul Herbrecht +16 more
TL;DR: It is demonstrated that an individual dose‐adjustment of ACVBP regimen was manageable in PTLD patients and favourably impacted on long‐term survival.
Journal Article
Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
Raoul Santucci,Dominique Levêque,Véronique Kemmel,Patrick Lutz,Anne-Cécile Gerout,Aurélia N'guyen,Aurélie Lescoute,Francis Schneider,Jean-Pierre Bergerat,Raoul Herbrecht +9 more
TL;DR: In line with the recent literature and given the prohibitive cost of glucarpidase, the cessation of proton pump inhibitors administration during methotrexate treatment is advocated.
Journal ArticleDOI
Long-term Hypokalemia in Acute Myeloid Leukemia
TL;DR: A 48-year-old man suffering from acute myeloid leukemia presented a hypokalemia that persisted almost constantly during 18 months despite total hematological remission, which appeared to be the main kaliopenic factor.